On March 20, 2025, Johnson & Johnson’s Tremfya® (guselkumab) received FDA approval for a label expansion for the treatment of Crohn’s Disease (CD). Tremfya® is the first and only interleukin (IL)-23 inhibitor offering both subcutaneous and intravenous induction options for adult patients with moderately to severely active Crohn’s disease. This approval marks the fourth indication for Tremfya® in the U.S., following moderate-to-severe plaque psoriasis in July 2017, active psoriatic arthritis in July 2020, and moderately to severely active ulcerative colitis in September 2024.
https://hubs.li/Q03dR8C-0
